

# East India Pharmaceutical Works Limited

Unlisted Share Financial Report

## Company Overview

East India Pharmaceutical Works manufactures a broad range of pharmaceutical formulations for domestic and export markets.

## Market Snapshot

CURRENT PRICE / SHARE <b>Rs 86.9</b>	MARKET CAP <b>58 Cr</b>	P/E RATIO <b>26.33</b>	P/B RATIO <b>0.78</b>
BOOK VALUE / SHARE <b>Rs 101.38</b>	FACE VALUE <b>Rs 10</b>	DEBT TO EQUITY <b>0.92</b>	RETURN ON EQUITY <b>14%</b>
LOT SIZE <b>250 shares</b>	TOTAL SHARES <b>66,74,858</b>		

Prices are indicative over-the-counter levels as of 07 July 2026. Actual deal prices may vary.

## Corporate Details

ISIN	<b>INE254X01017</b>
CIN	<b>U24231WB1936PLC008598</b>
PAN	<b>AAACE5779P</b>
Registrar (RTA)	<b>C B Management Services</b>
Depository	<b>NSDL &amp; CDSL</b>
Sector	<b>Healthcare</b>
Industry	<b>Pharmaceuticals</b>

## Income Statement (Rs Crore)

Particulars	2023	2024	2025
<b>Revenue</b>	<b>234</b>	<b>250</b>	<b>272</b>
Cost of Material Consumed	79	79	84
Change in Inventory	4	-0.4	8
Gross Margins	64.53%	68.56%	66.18%
Employee Benefit Expenses	77	90	94
Other Expenses	64	69	73
<b>EBITDA</b>	<b>10</b>	<b>12.4</b>	<b>13</b>
OPM	4.27%	4.96%	4.78%
Other Income	0.08	0.12	0.15
Finance Cost	5	5	6
Depreciation & Amortisation	2	3	2
<b>EBIT</b>	<b>8</b>	<b>9.4</b>	<b>11</b>
EBIT Margins	3.42%	3.76%	4.04%
<b>Profit Before Tax</b>	<b>2.4</b>	<b>4.5</b>	<b>4</b>
PBT Margins	1.03%	1.8%	1.47%
Tax	0.7	0.7	2
<b>Profit After Tax</b>	<b>1.7</b>	<b>3.8</b>	<b>2</b>
Net Profit Margin	0.73%	1.52%	0.74%
EPS	Rs 2.55	Rs 5.7	Rs 3

## Balance Sheet - Assets (Rs Crore)

Particulars	2023	2024	2025
Fixed Assets	15	14	13
Capital Work in Progress	0.2	0	1.35
Investments	0	0	0
Trade Receivables	109	123	149
Inventory	36	39	32
Other Assets	17.8	20	24.65
<b>Total Assets</b>	<b>178</b>	<b>196</b>	<b>220</b>

## Balance Sheet - Liabilities (Rs Crore)

Particulars	2023	2024	2025
Share Capital	6.67	6.67	6.67
Face Value	Rs 10	Rs 10	Rs 10
Reserves	46	49	51
Borrowings	44	48	53
Trade Payables	46	50	64
Other Liabilities	35.33	42.33	45.33
<b>Total Liabilities</b>	<b>178</b>	<b>196</b>	<b>220</b>

## Cash Flow Statement (Rs Crore)

Particulars	2023	2024	2025
<b>Profit Before Tax</b>	<b>2.4</b>	<b>4.5</b>	<b>4</b>
Operating Profit Before Working Capital	9.4	12.4	12.5
Change in Receivables	-19.8	-17.3	-26
Change in Inventories	7.8	-2.8	7
Change in Payables	1.5	11.3	16
Other Changes	0	0	-0.5
Working Capital Change	-10.5	-8.8	-3.5
Cash Generated From Operations	-1.1	3.6	9
Tax	-2	-1.3	-3
<b>Cash Flow From Operations</b>	<b>-3.1</b>	<b>2.3</b>	<b>6</b>
Purchase of PPE	-1.9	-1.3	-3.2
Sale of PPE	0.2	0.2	0.4
<b>Cash Flow From Investment</b>	<b>-1.7</b>	<b>-1.1</b>	<b>-2.8</b>
Borrowing	9.3	3	6
Dividend	-0.8	-0.4	-0.5
Equity	0	0	0
Others From Financing	-4.6	-5.5	-5.96
<b>Cash Flow from Financing</b>	<b>3.9</b>	<b>-2.9</b>	<b>-0.46</b>
<b>Net Cash Generated</b>	<b>-0.9</b>	<b>-1.7</b>	<b>2.74</b>
Cash at the Start	8.2	7.3	5.59
Cash at the End	7.3	5.6	8.33

## Key Ratios

Particulars	2023	2024	2025
Operating Profit Margin	4.27%	4.96%	4.78%
Net Profit Margin	0.73%	1.52%	0.74%
Earning Per Share (Diluted)	Rs 2.55	Rs 5.7	Rs 3

Source: Compiled by Neoma Capital research. Data as of FY2025. Figures may be restated in subsequent filings.